Grants per year
Personal profile
Certifications and Licenses
| Internal Medicine | |
| Medical Oncology | |
| Hematology |
Training Experience
| 2002 | Residency, Rush University Medical Center |
| 2005 | Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital) |
Education/Academic qualification
Medicine, MD, University of Chicago
… → 1999
Research interests
- Acute Leukemias
- Aplastic Anemia
- Bone Marrow Transplantation
- Chronic Leukemias
- Cord Stem Cell Transplant
- Hematological Malignancies
- Leukemia
- Myelodysplastic Syndrome
Fingerprint
Dive into the research topics where Olga Frankfurt is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #P-106-001: Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients with Respiratory Viral Infections After Hematopoietic Cell Transplant
Medpace Clinical Research LLC, AlloVir, Inc
1/22/21 → 1/22/24
Project: Research project
-
Prot #AML003: Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥60 Year
Novella Clinical, LLC, Rafael Pharmaceuticals, Inc.
5/1/19 → 5/1/22
Project: Research project
-
Impact of race on outcomes in intermediate-risk acute myeloid leukemia
Abraham, I. E., Patel, A. A., Wang, H., Galvin, J. P., Frankfurt, O., Liu, L. & Khan, I., Jul 2021, In: Cancer Causes and Control. 32, 7, p. 705-712 8 p.Research output: Contribution to journal › Article › peer-review
-
Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
DiNardo, C. D., Stein, A. S., Stein, E. M., Fathi, A. T., Frankfurt, O., Schuh, A. C., Döhner, H., Martinelli, G., Patel, P. A., Raffoux, E., Tan, P., Zeidan, A. M., de Botton, S., Kantarjian, H. M., Stone, R. M., Frattini, M. G., Lersch, F., Gong, J., Gianolio, D. A., Zhang, V. & 8 others, , Jan 1 2021, In: Journal of Clinical Oncology. 39, 1, p. 57-65 9 p.Research output: Contribution to journal › Article › peer-review
Open Access15 Scopus citations -
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/ refractory FLT3-ITD–mutant acute myeloid leukemia
Smith, C. C., Levis, M. J., Frankfurt, O., Pagel, J. M., Roboz, G. J., Stone, R. M., Wang, E. S., Severson, P. L., West, B. L., Le, M. H., Kayser, S., Lam, B., Hsu, H. H., Zhang, C., Bollag, G. & Perl, A. E., Apr 28 2020, In: Blood Advances. 4, 8, p. 1711-1721 11 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations -
An integrative approach reveals genetic complexity and epigenetic perturbation in acute promyelocytic leukemia: a single institution experience
Rahimi, N., Zhang, Y., Mina, A., Altman, J. K., Sukhanova, M., Frankfurt, O., Jennings, L., Lu, X., Behdad, A., Chen, Q., Chen, Y. H. & Gao, J., Sep 2019, In: Human pathology. 91, p. 1-10 10 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: A phase I trial
Gangat, N., Marinaccio, C., Swords, R., Watts, J. M., Gurbuxani, S., Rademaker, A., Fought, A. J., Frankfurt, O., Altman, J. K., Wen, Q. J., Farnoud, N., Famulare, C. A., Patel, A., Tapia, R., Vallapureddy, R. R., Barath, S., Graf, A., Handlogten, A., Zblewski, D., Patnaik, M. M. & 14 others, , Aug 15 2019, In: Clinical Cancer Research. 25, 16, p. 4898-4906 9 p.Research output: Contribution to journal › Article › peer-review
35 Scopus citations